Next Generation EGFR Inhibitors
|
|
- Emory Doyle
- 6 years ago
- Views:
Transcription
1 Next Generation EGFR Inhibitors Tony Mok MD Li Shu Fan Medical Foundation Professor of Clinical Oncology Dept. of Clinical Oncology The Chinese University of Hong Kong
2 EGFR TKIs First Generation -Gefitinib -Erlotinib -Icotinib Second Generation -Afatinib -Dacomitinib Third Generation Fourth Generation?
3 EGFR TKI First Generation -Gefitinib -Erlotinib -Icotinib Second Generation -Afatinib -Dacomitinib Third Generation Fourth Generation?
4 EGFR Exon 20 T790M ATP Erlotinib Erlotinib +T790M
5 IC50 1 st generation gefitinib, erlotinib 2 nd generation Afatinib, dacomitinib T790M L858R/ X19 del WT Clinical tolerable dose
6 3rd-generation EGFR TKI Irreversible binding occurs due to covalent bond with C797. Mutation selective + irreversible binding + EGFR WT sparing more potent against T790M and 100 less potent against EGFR WT) Cross D, et al. Cancer Discov. 2014;4:
7 Pyrimidine-based TKI IC50 (nm) H1975 IC50 (nm) PC9 GR Gefitinib Gefitinib CL-387,785 CL-387,785 HKI-272 HKI-272 WZ3146 WZ3146 WZ4002 WZ4002 WZ8040 WZ8040 Zhou and Janne Nature 2009
8 L858R/T790M Del19/T790M p = p = w Vehicle 2w Relative Tumor Volume % Vehicle WZ-4002 Vehicle WZ w WZ4002 2w Del19/T790M L858R/T790M w Vehicle 2w Tumor Size (mm 3 ) Vehicle WZ4002 Erlotinib Day Zhou et al. Nature w WZ4002 2w A431 Cells EGFR WT & amplified
9 A New Generation of T790M inhibition Avitinib HM61713 CO1686 AZD9291
10 AZD9291 (Osimertinib)
11 Phas e I AURA: Phase I dose expansion study Patients with T790M positive advanced NSCLC whose disease has progressed following either one prior therapy with an EGFR-TKI or following treatment with both EGFR-TKI and other anticancer therapy Rolling six design Escalation Cohort 1 20 mg Cohort 2 40 mg Cohort 3 80 mg Cohort mg Cohort mg Expansion Positive Positive Positive Positive Positive Negative Negative First-line Biopsy Tablet Cytology Negative First-line Biopsy
12 AURA: RR of osimertinib in T790M positive patients RR: 64% Janne et al NEJM 372:1689, 2015
13 Impact of dose on RR
14 PFS in T790M +ive and ive populations Median PFS at 9.6 months
15 AURA2: Phase II, open-label, single-arm study on osimertinib Primary objective To investigate the efficacy of AZD9291 by assessment of ORR (RECIST 1.1 BICR) Patients with confirmed EGFRm locally advanced or metastatic NSCLC who have progressed following prior therapy with an approved EGFR-TKI Key inclusion criteria Aged 18 ( 20 in Japan) Confirmation of tumor EGFR mutation associated with EGFR-TKI At least one lesion suitable for accurate repeated measurements WHO performance status 0 or 1 Acceptable organ function Stable brain metastases allowed Central T790M mutation testing* of biopsy sample collected following confirmed disease progression T790M positive (n=210) T790M negative AZD mg once daily Not eligible for enrollment *Mitsudomi et al WCLC 2015
16 Tumor response by independent central review Best percentage change from baseline in target lesion all patients Complete response Partial response Stable disease Progressive disease Not evaluable Confirmed objective response Total ORR 71% (95% CI 64, 77) Complete response, n (%) Partial response, n (%) Stable disease 6 weeks, n (%) Progressive disease, n (%) DCR 2 (1) 139 (70) 41 (21) 15 (8) 92% (95% CI 87, 95) NOTE: Investigator-assessed ORR was also 71% (95% CI 64, 77) Data cut-off: May 1, Population: evaluable for response set (n=199). *Represents imputed values: if it is known that the patient has died, has new lesions or progression of non-target lesions, has withdrawn due to disease progression, and has no evaluable target lesion (before or at progression) assessments, best change will be imputed as 20%; ORR defined as the number (%) of patients with at least one visit response of complete response or partial response that was confirmed at least 4 weeks later; Response required confirmation after 4 weeks; Stable disease 6 weeks included the RECIST visit window (±7 days) CI, confidence interval; DCR, disease control rate (complete response + partial response + stable disease)
17 Probability of response Probability of progression-free survival Duration of response and progression-free survival Duration of response* (BICR) Progression-free survival* (BICR) Osimertinib approved by FDA on Nov , (2.5 years since the first patient enrollment) AZD mg Censored observations AZD mg Censored observations Number of patients at month: Month Number of patients at risk: Month KM-based estimated Total Median DoR, months (95% CI) Remaining in response, % (95% CI) 6 months 9 months 7.8 (7.1, NC) Maturity: 27% 75 (65, 82) NC (NC, NC) Range of DoR, months KM-based estimated Total Median PFS,** months (95% CI) 8.6 (8.3, 9.7) Maturity: 38% Remaining alive and progression free, % (95% CI) 6 months 9 months Median follow-up for PFS 70 (63, 76) 48 (36, 58) 6.7 months Data cut-off: May 1, *Green dotted lines represent 95% CI; Calculated using the Kaplan-Meier technique; Population: evaluable for response analysis set; Population: full analysis set (n=210); DoR is the time from the first documentation of complete/partial response (that is subsequently confirmed) until the date of progression or death in the absence of disease progression; **PFS is the time from date of first dosing until the date of objective disease progression or death; Median PFS (months) by investigator assessment was NC (95% CI 9.3, NC). Maturity: 37% DoR, duration of response; KM, Kaplan-Meier; NC, not calculable; PFS, progression-free survival
18 Phase I Pooled analysis of AURA 1+2 AURA Ph I/II Patients with T790M positive advanced NSCLC whose disease has progressed following either one prior therapy with an EGFR-TKI or following treatment with both EGFR-TKI and other anticancer therapy Rolling six design AURA2 Ph II Patients with confirmed EGFRm locally advanced or metastatic NSCLC who have progressed following prior therapy with an approved EGFR-TKI Escalation Cohort 1 20 mg Cohort 2 40 mg Cohort 3 80 mg Cohort mg Cohort mg Positive Positive Positive Positive Positive Negative Negative Negative T790M cohorts Central T790M mutation testing* of biopsy sample collected following confirmed disease progression First-line First-line Expansion Biopsy Tablet Cytology Biopsy T790M positive T790M negative AURA Phase II Extension (n=201) Osimertinib 80 mg QD Pooled Phase II AURA2 (n=210) Osimertinib 80 mg QD RR and PFS on 411 patients with T790M mutation Not eligible for enrollment AURA Ph I data cut-off 4 January, 2016; AURA pooled Ph II data cut-off 1 November, *The EGFR T790M mutation status of the patient s tumour was prospectively determined by the designated central laboratory using the cobas EGFR Mutation Test (Roche Molecular Systems) by biopsy taken after confirmation of disease progression on the most recent treatment regimen. Data from cohorts in grayed out boxes are not included in the analyses reported here. QD, once daily
19 Largest cohort (n=411) of T790M +ive population on osimertinib 80mg Median PFS: 11 months Yang et al ELCC 2016
20 AURA 3 Study Design Randomise ~470 patients 2:1 Central testing of ~ 1540 biopsy samples T790M+ (n=470) AZD9291 (80 mg p.o. qd) (n=407) Platinum-based doublet chemotherapy* every 3 weeks (n=203) Primary endpoint: PFS T790M- Not eligible for enrolment *Pemetrexed 500 mg/m 2 + carboplatin AUC5 or Pemetrexed 500 mg/m 2 + cisplatin 75 mg/m 2 P PI: T Mok YL Wu AUC5, area under the plasma concentration time curve 5 mg/ml 1 per minute; EGFRm+, EGFR mutation-positive; EGFR-TKI, EGFR tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; p.o., orally; qd, once daily; T790M+, T790M mutation-positive; T790M-, T790M mutation-negative
21 Best timing for osimertinib? Dx of EGFR mutation positive lung cancer (+/- T790M) EGFR TKI Presence of T790M in plasma cfdna Clinical progression and T790M +ive To be supported by FLAURA?? Supported by AURA 1/2/3
22 Potential study concept: Osimertinib for molecular progression Time to osimertinib Failure (TTF) Monthly cfdna for T790M for patient on first line TKI Plasma positive for T790M without radiologic progression Continue the same TKI till radiologic progression Osimertinib osimertinib Primary endpoint: TTF or OS Time to osimertinib Failure (TTF)
23 Rociletinib (CO-1686)
24 Phase I/II dose escalation study T790M positive Confirmed RR by central review in 46 pts = 59% T790M negative Sequist et al NEJM 2015
25 Toxicity signal: hyperglycemia M502
26 TIGER-X: Phase 1/2 Trial of Rociletinib Key eligibility criteria Advanced or recurrent NSCLC with a documented activating EGFR mutation Prior treatment with EGFR-directed therapy Recent biopsy available or willing to undergo a new on-study biopsy; plasma samples collected Phase 2 only Disease progression while on treatment with EGFR-directed therapy T790M-positive biopsy at the time of entering study Treated stable CNS metastases are allowed Phase 1 (Dose Escalation) Phase 2 Expansion Cohorts CO-1686 Treatment 21-day cycles; escalate to MTD 2nd-line patients PD upon 1 immediate prior TKI >2nd-line patients PD upon 2 TKI or chemotherapy 500mg BID 625mg BID 750mg BID Key outcome measures Safety Tolerability PK profile ORR 26
27 SLD Change from Baseline (%) Best Response to Rociletinib (All Doses) in 256 Centrally Confirmed Tissue T790M+ Patients mg 625mg 750mg 1000 mg Total N ORR (%) DCR (%) Nov 2015: FDA denied the fast track application 500mg BID HBr 625mg BID HBr 750mg BID HBr 1000mg BID HBr + Ongoing May 2016: Cessation of future development of Rociletinib SLD, sum of longest diameters *3 patients currently have no evaluable baseline lesions per database and are omitted from this analysis 27
28 Olmutinib (HM61713)
29 HM61713 = BI
30 Phase I/II study in patients with EGFR TKI pre-treated NSCLC Dose escalation (N=66) 1 T790M-positive or negative Progression on 2 prior therapies, including EGFR TKI 75 mg 150 mg 100 mg 200 mg 250 mg 400 mg 300 mg 650 mg 500 mg 800 mg 1200 mg Expansion Part 2 (N=76; ongoing) T790M-positive (central test) Progression on 1 prior EGFR TKI Expansion Part 1 (N=83) 1 T790M positive or negative Progression on prior EGFR TKI 1. Park K, et al Santa Monica 2016.
31 Tumor volume change (%) ORR and tumor shrinkage in T790M+ patients (independent review) PR (n=43) Confirmed PR (n=32) SD (n=20) NE (n=3) PD (n=3) Evaluable patients (n=69) OR (confirmed and unconfirmed), n (%) 43 (62) Disease control, n (%) Confirmed OR, n (%) SD, n (%) 63 (91) 32 (46) 31 (45) PD, n (%) 3 (4) NE, n (%) 3 (4) DoR is immature; in patients with confirmed OR, response duration ranged between 6 and 31 weeks at data cut-off DoR, duration of response; OR, objective response; ORR, objective response rate; NE, not evaluable; PD, progressed disease; PR, partial response; SD, stable disease
32 Most frequent treatment-related adverse events at 800 mg QD BI (HM61713) 800 mg QD (n=76) AE, n (%) All grades Grade 3 Diarrhea 42 (55) 0 Rash 29 (38) 4 (5) Nausea 28 (37) 0 Pruritus 27 (36) 1 (1) Dry skin 22 (29) 1 (1) Palmar-plantar erythrodysesthesia syndrome 22 (29) 2 (3) Decreased appetite 20 (26) 0 Skin exfoliation 16 (21) 0 Vomiting 12 (16) 2 (3) Abdominal pain 11 (14) 0 ALT increased 11 (14) 2 (3) Abdominal pain upper 10 (13) 0 Constipation 10 (13) 0 Pyrexia 9 (12) 0 AST increased 9 (12) 2 (3) Platelet count decreased 9 (12) 0 Dyspepsia 8 (11) 0 Fatigue 8 (11) 0 AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase
33 LUX Lung Program
34 ELUXA Lung Program ELUXA 1: Phase II trial in second-line patients with EGFR T790M+ NSCLC ELUXA 2: Phase III trial of second-line BI vs platinumdoublet chemotherapy in patients with EGFR T790M+ NSCLC ELUXA 3: Phase III trial of first-line BI vs afatinib in EGFR M+ NSCLC ELUXA 4: Phase I/II trial of BI in Japanese patients with EGFR T790M+ NSCLC
35 EGF816
36 Phase I/II study design Tan et al ASCO 2015
37 Tumor response (n=53) Tan et al ASCO 2015
38 Skin rash
39 Avitinib (AC0010)
40 Phase I dose Escalation/Expansion (BID) in T790M + NSCLC Patients (NCT )
41 Best Change in Target Lesion and Objective Response Rate (N=36) All doses level (N=36) ORR: 36%; DCR (PR+SD): 97% (35/36) Therapeutic doses level (200 mg to 300 mg, N=19) ORR: 58%; DCR (PR+SD): 95% (18/19) Wu YL Santa Monic
42 EGFR TKI First Generation -Gefitinib -Erlotinib -Icotinib Second Generation -Afatinib -Dacomitinib Third Generation Fourth Generation?
43 Evolution of resistance mechanisms in EGFR mutant lung cancer following successive EGFR TKI therapy Erlotinib T790M+ Osimertinib T790M+ plus C797S T790M- T790M+ plus unknown resistance EGFR activating mutation = EGFR T790M = EGFR C797S = resistance mechanism due to activation of bypass or downstream signaling pathway T790M plus unknown resistance Loss of T790M Oxnard et al. IASLC 2015, and Planchard et al. Ann Oncol 2015
44 C) EGFR - + C797S 1 um WZ - + pegfr 121 Pt Res # 1 EGFR perk EGFR C797 Covalent binding site of all mutant selective EGFR Inhibitors MGH121 pt MGH121 Res # ERK ps6 S6 Actin Gly 796 Cys 797 Leu 798 G G C T G C C T C Gly 796 Cys/Ser 797 Leu 798 G G C T G/C C C T C MGH121 pt MGH121 Res # 1 Zhou et al. Nature, 2009; Thress et al, Nature Medicine, 2015; 2 Oxnard et al. IASLC 2015; 3 Song et al. JTO 2016
45 Reported Resistance Mechanisms to Rociletinib and Osimertinib (n=34) SCLC/T790-wt 9% C797S/T790M 21% T790M Maintained (No additional resistance mechanism identified) 35% Her2 Amp/T790-wt 3% MET Amp/T790-wt 3% T790M "Lost" 29% Thress KS, Paweletz CP, Felip E, et al, Nat Med. 2015;21(6): Piotrowska Z, Niederst MJ, Karlovich CA, et al, Cancer Discov. 2015;5(7): Yu HA, Tian SK, Drilon AE, et al, JAMA Oncol. 2015;1(7): Planchard D, Loriot Y, André F, et al, Ann Oncol. 2015;26(10): Kim TM, Song A, Kim DW, et al, J Thorac Oncol Courtesy Zofia Piotrowska
46 EGFR L798I αd helix PNAS, 1991, 88, Jeabong Jang and Nathanael Gray
47 Chabon et al ASCO 201
48 The first report of a potential molecule targeting C797S
49 EGFR Allosteric Inhibitor: EAI-045
50 Limited activity as an single agent EAI045 binds the C- Helix, which can be displaced by dimerization of EGFR Prevention of dimerization may improve the potency of EAI045 in C797S mutation.
51 Summary AZD9291 (Osimertinib) Approved therapy for T790M+ disease RR at 64%, PFS 9.6month CO1686 (Rociletinib) RR is not confirmed at the FDA submission Hyperglycemia from active metabolite HM61713 (Olmutinib) Enter into phase III study after a partnership with BI EGF816 Phase I response rate at 75% Unusual maculopapular rash Fourth Generation? Targeting C797S Allosteric molecule EAI045
52 I am so confused!!
Treatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationRociletinib (CO-1686) April, 2015
Rociletinib (CO-1686) April, 2015 Lung adenocarcinoma is increasingly treated according to driver mutation Lung cancer incidence Worldwide: 1.2M cases per year UK: 43K cases per year Activating mutations
More informationEmerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC
Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Keunchil Park, MD, PhD Samsung Medical Center, Sungkyunkwan University School of Medicine Faculty Disclosure Consulting
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationIMPORTANT PATHWAYS TO TARGET IN (ADVANCED) NSCLC:
IMPORTANT PATHWAYS TO TARGET IN (ADVANCED) NSCLC: A focus on EGFR-inhibition and implications for clinical practice Floriana Morgillo, MD PhD and Morena Fasano, MD PhD Faculty of Medicine, Università degli
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationAgenda. 6:30pm 7:00pm. Dinner. 7:00pm 7:15pm. NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice.
Agenda 6:30pm 7:00pm Dinner 7:00pm 7:15pm Welcome and Introductions Natasha Leighl, MD 7:15pm 7:50pm 7:50pm 8:00pm NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice Questions
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationAfatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data
Afatinib in patients with EGFR mutation-positive NSCLC harboring uncommon mutations: overview of clinical data Oscar Arrieta, 1 Pedro De Marchi, 2 Nobuyuki Yamamoto, 3 Chong-Jen Yu, 4 Sai-Hong I Ou, 5
More informationTargeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation
Targeting Acquired Resistance to EGFR Kinase Inhibitors: Beyond T790M Mutation James Chih-Hsin Yang, MD, PhD National Taiwan University Hospital National Taiwan University Cancer Center Taipei, Taiwan
More informationEGFR TKI sequencing: does order matter?
EGFR TKI sequencing: does order matter? Nicolas Girard Thorax Institut Curie-Montsouris, Paris, France In Switzerland, afatinib is approved as monotherapy for patients with non-small cell lung cancer (Stage
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationDiagnostic with alternative sample types (liquid biopsy)
MOLECULAR DIAGNOSTICS OF EGFR AND T790M MUTATIONS CHALLENGES AND SOLUTIONS Diagnostic with alternative sample types (liquid biopsy) James CH Yang, MD, PhD Director, Professor, Graduate Institute of Oncology
More informationActivity of osimertinib and the selective RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement.
Activity of osimertinib and the selective RET inhibitor in an EGFR-mutant patient with acquired RET rearrangement. Z Piotrowska 1, H Isozaki 1, JK Lennerz 1, S Digumarthy 1, JF Gainor 1, N Marcoux 1, M
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationOsimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell
Editorial Osimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell lung cancer Chong-Kin Liam Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
More informationNovel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial 2014-309-00CH1 Presenter: Jifang Gong, Beijing Cancer Hospital Lin Shen 1, Li Zhang 2, Hongyun Zhao 2, Wenfeng Fang 2,
More informationTargeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
More informationManagement of EGFR-Mutation Positive Metastatic Non-Small Cell Lung Cancer
Management of EGFR-Mutation Positive Metastatic Non-Small Cell Lung Cancer Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center Rogerio Lilenbaum, MD Yale Cancer Center/Smilow Cancer Hospital EGFR Mutation
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationB I ABOUT BI DISEASE AREA & MECHANISM OF ACTION. For journalists outside UK/US/Canada only B A C K G R O U N D E R
For journalists outside UK/US/Canada only B I 1 4 8 2 6 9 4 1. About BI 1482694 2. Disease area & mechanism of action 3. Development status 4. Data overview 1. ABOUT BI 1482694 BI 1482694* (HM61713**)
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationPROGRESSION AFTER THIRD GENERATION TKI
PROGRESSION AFTER THIRD GENERATION TKI What next? National Cancer Center Hospital Yuichiro Ohe, MD Name of lead presenter Yuichiro Ohe employee of company and/or profit-making organization adviser of company
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationNew options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña
New options for old and new targets in NSCLC Rosario García Campelo Medical Oncology Unit University Hospital A Coruña Phase II GOAL TRIAL DESIGN Key inclusion criteria Patients with locally advanced or
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationOverall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR
Overall survival with afatinib versus chemotherapy in patients with NSCLC harboring common EGFR mutations: subgroup analyses by race/ethnicity in LUX-Lung 3 and LUX-Lung 6 Yi-Long Wu, 1 Lecia V Sequist,
More informationBalazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center
Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim
More informationOsimertinib: a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma
Editorial : a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma Niki Karachaliou 1, Feliciano Barron Barron 2, Santiago Viteri 3, Miguel Angel Molina 4, Rafael
More informationAFATINIB* 1. WHAT IS AFATINIB? 2. HOW DOES AFATINIB WORK? B A C K G R O U N D E R
AFATINIB* B A C K G R O U N D E R 1. What is afatinib? 2. How does afatinib work? 3. Data overview: the LUX-Lung clinical trial programme 4. Data overview: the LUX-Head and Neck clinical trial programme
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationManagement of EGFR-mutant NSCLC. Jonathan Riess, MD, MS Assistant Professor UC Davis Comprehensive Cancer Center
Management of EGFR-mutant NSCLC Jonathan Riess, MD, MS Assistant Professor UC Davis Comprehensive Cancer Center Disclosures Research Funding: Merck, Novartis, AstraZeneca, Millenium Consulting: AbbVie,
More informationLong term survival in EGFR positive NSCLC patient. Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV
Long term survival in EGFR positive NSCLC patient Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV Medical history and diagnosis Male, caucasian 60 years old Former smoker (stop > 15 years)
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationMaking the first decision: EGFR mutation-positive NSCLC in the advanced setting
ELCC May 217, Switzerland Making the first decision: EGFR mutation-positive NSCLC in the advanced setting Noemí Reguart, MD, PhD Hospital Clínic de Barcelona, Spain Disclosures Consultant or Advisory Role
More informationTKI en primera línea EGFR mutado:importancia del equilibrio eficacia tolerabilidad
TKI en primera línea EGFR mutado:importancia del equilibrio eficacia tolerabilidad Dra Pilar Lianes Barragan Consorcio Sanitario del Maresme (Barcelona) Indice Epidemiología TKI en primera línea Eficacia
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer
ALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer Dr. Ben Solomon Medical Oncologist, Thoracic Oncology Peter MacCallum Cancer Centre Melbourne, Australia Dr. D.
More informationOsimertinib (AZD9291) a science-driven, collaborative approach
Annals of Oncology Advance Access published March 8, 2016 1 Osimertinib (AZD9291) a science-driven, collaborative approach to rapid drug design and development A. Yver Global Medicines Development, AstraZeneca,
More informationBalazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center
Balazs Halmos, M.D. Division of Hematology/Oncology Columbia University Medical Center Eli-Lilly Pfizer Astellas Daiichi-Sankyo Oncothyreon Astex Astra-Zeneca Bristol-Myers-Squibb Novartis Roche Boehringer-Ingelheim
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationASCO Highlights and Controversies in advanced Lung Cancer. Torino, 11 giugno 2015
ASCO 2015 Highlights and Controversies in advanced Lung Cancer Torino, 11 giugno 2015 Paolo Bironzo AOU S Luigi Gonzaga - Orbassano Scuola di Specializzazione in Oncologia Medica Università di Torino What
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationFILED: NEW YORK COUNTY CLERK 03/29/ :57 PM INDEX NO /2016 NYSCEF DOC. NO. 59 RECEIVED NYSCEF: 03/29/2017 EXHIBIT J
EXHIBIT J ASCO Clinical Data Update May 31, 2015 The Langham Hotel, Chicago Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations
More informationSequence or intercalation of use of targeted agents and Chemotherapy Definition of progression under TKI
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER Strategic Approaches Sequence or intercalation of use of targeted agents and Chemotherapy Definition of progression under TKI Yi-Long Wu Guangdong
More informationBeyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy
Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Oncogenic drivers in NSCLC Certain tumours arise as a result of aberrant activation
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationONT-380 and HER2+ Breast Cancer
ONT-380 and HER2+ Breast Cancer Diana F. Hausman, MD CMO, VP Clinical Development Oncothyreon Inc. PNW Bio February 10 2015 Copyright 2014 Copyright Oncothyreon 2014 Oncothyreon Oncothyreon Leading Oncology
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jänne PA, Yang JC-H, Kim D-W, et al. AZD9291 in EGFR inhibitor
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More information14,30 18,20. II Sessione. Moderatori: Giovanni Apolone, Roberto Labianca
14,30 18,20 II Sessione Moderatori: Giovanni Apolone, Roberto Labianca 15,10 15,30 Ca polmonare (never smokers): attualità e prospettive di ricerca Giulio Metro Ca polmonare (never smokers): attualità
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationClinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST)
Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) Michael Heinrich 1, Robin Jones 2, Margaret von Mehren 3, Patrick
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationDCC-2618, a novel pan-kit and PDGFR
DCC-2618, a novel pan-kit and PDGFRα Kinase switch control inhibitor demonstrates encouraging activity in patients (pts) with Gastrointestinal Stromal Tumors (GIST) N. Somaiah, A. Razak, M. Gordon, F.
More informationEditorial Process: Submission:10/27/2017 Acceptance:05/25/2018
DOI:10.22034/APJCP.2018.19.7.1761 TKI by Liquid Biopsy RESEARCH ARTICLE Editorial Process: Submission:10/27/2017 Acceptance:05/25/2018 A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted
More informationPost-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report)
Post-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report) Nobuyuki Yamamoto, 1 Toshihiro Nukiwa, 2 Yoichi Nakanishi,
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationBest of ASCO 2014: Highlights in Metastatic Non-Small Cell Lung Cancer
Best of ASCO 2014: Highlights in Metastatic Non-Small Cell Lung Cancer Howard (Jack) West, M JackWestM@gmail.com @JackWestM Swedish Cancer Institute Seattle, WA Best of ASCO 2014 Seattle, WA Learning Objectives
More informationImproving Therapy for EGFR-Mutant Lung Cancers. Zosia Piotrowska, MD Instructor, Harvard Medical School Massachusetts General Hospital Cancer Center
Improving Therapy for EGFR-Mutant Lung Cancers Zosia Piotrowska, MD Instructor, Harvard Medical School Massachusetts General Hospital Cancer Center Disclosures- Zofia Piotrowska Consulting- AstraZeneca,
More informationJ. C.-H. Yang 1, L.V. Sequist 2, S. L. Geater 3, C.-M. Tsai 4, T. Mok 5, M. H. Schuler 6, N. Yamamoto 7, D. Massey 8, V. Zazulina 8, Yi-Long Wu 9
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings from three prospective trials of afatinib in EGFR mutation-positive lung cancer J. C.-H. Yang 1, L.V. Sequist
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationAURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?
Editorial Page 1 of 5 AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Terry L. Ng, D. Ross Camidge Division of Medical Oncology, Department of Medicine, University of Colorado
More informationCorrespondence should be addressed to Kumar Prabhash;
Hindawi Chemotherapy Research and Practice Volume 2017, Article ID 8196434, 4 pages https://doi.org/10.1155/2017/8196434 Clinical Study Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating
More informationGIOTRIF (AFATINIB*) For journalists outside the US/UK/Canada only 1. WHAT IS GIOTRIF (AFATINIB*)? 2. HOW DOES GIOTRIF (AFATINIB*) WORK?
For journalists outside the US/UK/Canada only GIOTRIF (AFATINIB*) 1. What is GIOTRIF (afatinib*)? 2. How does GIOTRIF (afatinib*) work? 3. Data overview 4. Clinical potential 5. GIOTRIF (afatinib*) approval
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationLihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article
Original Article MET overexpression coexisting with epidermal growth factor receptor mutation influence clinical efficacy of EGFR-tyrosine kinase inhibitors in lung adenocarcinoma patients Lihong Ma 1
More informationT790M como marcador predictivo de respuesta. Mariano Provencio
T790M como marcador predictivo de respuesta Mariano Provencio CASO 1 Provencio et al submitted. Provencio et al submitted. C + 450 días: Progresión Taponamiento cardiaco Distress respiratorio ingreso por
More informationHacia una mayor individualización clínica en el CPNM. J.M. Sánchez Torres H.U. Princesa, Madrid
Hacia una mayor individualización clínica en el CPNM J.M. Sánchez Torres H.U. Princesa, Madrid Lung cancer histologic subtypes NSCLC (80-85%) SCLC (15-20%) Squamous carcinoma (25 30%) Non-squamous carcinoma
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More information